H pylori antibiotic resistance: Prevalence, importance, and advances in testing

Gut

Volumn 53, Issue 9, 2004, Pages 1374-1384

  Megraud F ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; JOSAMYCIN; LANSOPRAZOLE; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; NITROIMIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL MUTATION; BACTERIAL STRAIN; CLINICAL TRIAL; DRUG POTENTIATION; DYSPEPSIA; ERADICATION THERAPY; GASTROINTESTINAL DISEASE; GYNECOLOGIC INFECTION; HEALTH SURVEY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS; NONHUMAN; PARASITOSIS; PEPTIC ULCER; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TOOTH INFECTION; TREATMENT FAILURE;

ADULT; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 4344592305     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.022111     Document Type: Review

References (154)

1. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 1997;41:8-13.
2. The report of the Digestive Health Initiative International Update on Helicobacter pylori. Gastroenterology 1997;113:S4-5.
3. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12.
4. Hunt RH, Fallone CA, Thomson ABR. Canadian Helicobacter pylori Consensus Conference update: infections in adults. Can J Gastroenterol 1999;13:213-17.
5. Coelho LG, Leon-Barua R, Quigley EMM, et al. Latin-American consensus conference on Helicobacter pylori infection. Am J Gastroenterol 2000;95:2688-91.
6. Malfertheiner P, Mégraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
7. Mégraud F, Lamouliatte H. The treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-43.
8. Mégraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998;115:1278-82.
9. Mégraud F, Hazell S, Glupczynski Y. Antibiotic susceptibility and resistance. In: Mobley HLT, Mendz GL, Hazell SL, eds. Helicobacter pylori: physiology and genetics. Washington, DC: ASM Press, 2001:511-30.
10. Boyanova L, Spassova Z, Krastev Z, et al. Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years. Diagn Microbiol Infect Dis 1999;34:309-13.
11. Bago J, Halle ZB, Strinic D, et al. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication-a randomised controlled trial. Wien Klin Wochenschr 2002;114:448-53.
12. Mégraud F. Surveillance de la résistance de Helicobacter pylori aux antibiotiques. In: Surveillance nationale des maladies infectieuses 1998-2000. St Maurice, France: Institut de Veille Sanitaire, 2003:327-9.
13. Wolle K, Leodolter A, Malfertheiner P, et al. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002;51:705-9.
14. Dammann HG, Folsch UR, Hahn EG, et al. Eradication of H. pylori. with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration, Helicobacter, 2000;5:41-51.
15. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003;35:541-5.
16. Pilotto A, Rassu M, Leandro G, et al. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 2000;32:763-8.
17. Debets-Ossenkopp YJ, Herscheid A, Pot RGJ, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 1999;43:511-15.
18. Cabrita J, Oleastro M, Matos R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000;46:1029-31.
19. Cuchi Burgos E, Forne Bardera M, Quintana Riera S, et al. Evolution of the sensitivity of 235 strains of Helicobacter pylori from 1995 to 1998 and impact of antibiotic treatment Enferm Infecc Microbiol Clin 2002;20:157-60.
20. Mégraud F, Lehn N, Lind T, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicentre trial: the MACH 2 study. Antimicrob Agents Chemother 1999;43:2747-52.
21. Parsons HK, Carter MJ, Sanders DS, et al. Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 2001;15:1473-8.
22. Teare L, Peters T, Saverymuttu S, et al. Antibiotic resistance in Helicobacter pylori. Lancet 1999;353:242.
23. Torres J, Camorlinga-Ponce M, Perez-Perez G, et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001;39:2677-80.
24. Osato MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001;161:1217-20.
25. Laine L, Fennerty MB, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicentre, double-blind trials. Am J Gastroenterol 2000;95:3393-8.
26. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicentre, North American trial. Am J Gastroenterol 2003;98:562-7.
27. Prazeras Magalhaes P, De Magalhaes Queiroz DM, Campos Barbosa DV, et al. Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob Agents Chemother 2002;46:2021-3.
28. Mohammadi M, Doroud D, Massarrat S, et al. Clarithromycin resistance in Iranian H. pylori strains before introduction of clarithromycin. Helicobacter 2003;8:79-80.
29. Samra Z, Shmuely H, Niv Y, et al. Resistance of Helicobacter pylori isolated in Israel to mefronidazole, clarithromycin, tetracycline, amoxicillin and cefixime. J Antimicrob Chemother 2002;49:1023-6.
30. Ling TKW, Leung WK, Lee CC, et al. The antimicrobial susceptibility of Helicobacter pylori in Hong Kong (1997-2001). Helicobacter 2002;7:327-9.
31. Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002;7:306-9.
32. Kato M, Yamaoka Y, Kim JJ, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000;44:2214-16.
33. Kim JJ, Reddy R, Lee M, et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001;47:459-61.
34. Eun CS, Han DS, Park JY, et al. Changing pattern of antimicrobial reistance of Helicobacter pylori in Korean patients with peptic ulcer diseases. J Gastroenterol 2003;38:436-41.
35. Teo EK, Fock KM, Ng TM, et al. Metronidazole-resistant Helicobocter pylori in an urban Asian population. J Gastroenterol Hepatol 2000;15:494-7.
36. Lui SY, Yeah KG, Ho B. Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population. J Clin Micnobiol 2003;41:5011-14.
37. Fraser AG, Moore L, Hackett M, et al. Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit. Aust N Z J Med 1999;29:512-16.
38. Crone J, Granditsch G, Huber WD, et al. Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. J Pediatr Gastroenterol Nutr 2003;36:368-71.
39. Bontems P, Devaster JM, Corvaglia L, et al. Twelve year observation of primary and secondary antibiotic-resistant Helicobacter pylori strains in children. Pediatr Infect Dis J 2001;20:1033-8.
40. Boyanova L, Koumanova R, Gergova G, et al. Prevalence of resistant Helicobocter pylori isolates in Bulgarian children. J Med Microbiol 2002;51:786-90.
41. Kalach M, Gergeret M, Benhamou PH, et al. High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol 2001;39:394-7.
42. Dzierzanowska-Fangrat K, Rozynek E, Jozwiak P, et al. Primary resistance to clarithromycin in clinical strains of Helicobacter pylori isolated from children in Poland. Int J Antimicrob Agents 2001;18:387-90.
43. Lopez-Brea M, Martinez MJ, Domingo D, et al. A 9 year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children. J Antimicrob Chemother 2001;48:295-7.
44. Glupczynski Y, Mégraud F, Lopez-Brea M, et al. European multicenter survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2000;11:820-3.
45. Boyanova L, Mentis A, Gubina M, et al. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 2002;8:388-96.
46. Fallone CA. Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada. Can J Gastroenterol 2000;14:879-82.
47. Taneike I, Goshi S, Tamura Y, et al. Emergence of clarithromycin- resisfanf Helicobocter pylori (CRHP) with o high prevalence in children compared with their parents. Helicobacter 2002;7:297-305.
48. Loivukene K, Maaroos HI, Kolk H, et al. Prevalence of antibiotic resistance of Helicobacter pylori isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regimens. Clin Microbiol Infect 2002;8:598-603.
49. Cars O, Mölstad S, Melander Z. Variation in antibiotic use in the European Union. Lancet 2001;357:1851-3.
50. Heep M, Kist M, Strobel S, et al. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000;19:538-41.
51. Lourent J, Mégraud F, Fléjou JF, et al. A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2001;15:1787-93.
52. Birac C, Bouchard S, Camou C, et al. Six year follow-up of resistance to antibiotics of Helicobacter pylori in Bordeaux, France. Gut 1999;45(suppl 3):A107.
53. Broutet N, Tchamgoue S, Pereira E, et al. Risk factors for failure of Helicobacfer pylori therapy-results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003;17:99-109.
54. Kist M, Glocker E, Wolf B, et al. ResiNet-A nationwide German sentinel study on development and risk factors of antimicrobial resistance in Helicobacter pylori. Helicobacter 2003;8:465.
55. Broutet N, Marais A, Lamouliatte H de Mascarel A, et al. cagA status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in non-ulcer dyspeptic patients. J Clin Microbiol 2001;39:1319-22.
56. Katicic M, Ticak M, Kalenic S, et al. Sensitivity of Helicobacter pylori to metronidazole and macrolides in GERD/NUD and peptic ulcer patients with Helicobacter pylori eradication failure. Helicobacter 2003;8:471.
57. Mégraud F. Helicobacter pylori and macrolides. In: Schönfeld W, Kirst HA, eds. Macrolide antibiotics. Berlin: Birkhäuser Verlag, 2002:243-60.
58. Debets-Ossenkopp YJ, Brinkman AB, Kuipers EJ, et al. Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 1998;42:2749-51.
59. Mégraud F, Camou-Juncas C, Occhialini A, et al. Helicobacter pylori resistance levels to clarithromycin remain stable. Gastroenterology 1996;110:A192.
60. Hulten K, Gibreel A, Sköld O, et al. Macrolide resistance in Helicobacter pylori: Mechanism and stability in strains from clarithromycin-treated patients. Antimicrob Agents Chemother 1997;41:2550-3.
61. Xia H, Buckley M, Keane CT, et al. Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother 1996;37:473-81.
62. Fontana C, Favaro M, Minelli S, et al. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimcirob Agents Chemother 2002;46:3765-9.
63. Alarcon T, Vega AE, Domingo D, et al. Clarithromycin resistance among Helicobacter pylori strains isolated from children: prevalence and study of mechanism of resistance by PCR-restriction fragment length polymorphism analysis. J Clin Microbiol 2003;41:486-99.
64. Umegaki N, Shimoyama T, Nishiya D, et al. Clarithromycin-resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Japan. J Gastroenterol Hepatol 2000;15:906-9.
65. Kim KS, Kang JO, Eun CS, et al. Mutations in the 23S rRNA gene of Helicobacter pylori associated with clarithromycin resistance. J Korean Med Sci 2002;17:599-603.
66. Yang YJ, Yang JC, Jeng YM, et al. Prevalence and rapid identification of clarithromycin-resistant Helicobocter pylori isolates in children. Pediatr Infect Dis J 2001;20:062-6.
67. Gerrits MM, Schuijffel D, van Zwet AA, et al. Alterations in penicillin-binding protein 1A confer resistance to β-lactam antibiotics in Helicobacter pylori. Antimicrob Agents Chemother 2002;46:2229-33.
68. van Zwet AA, Vandenbroucke-Grauls CM, Thijs JC, et al. Stable amoxcillin resistance in Helicobacter pylori. Lancet 1998;352:1595.
69. Deloney CR, Schiller NL. Characterization of an in vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother 2000;44:3368-73.
70. Okamoto T, Yoshiyama H, Nakazawa T, et al. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother 2002;50:849-56.
71. Paul R, Postius S, Melchers K, et al. Mutations of the Helicobacter pylori genes rdxA and pbp1 cause resistance against metronidazole and amoxicillin. Antimicrob Agents Chemother 2001;45:962-5.
72. Dore MP, Graham DY, Sepulveda AR. Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori. Helicobacter 1999;4:154-61.
73. Kwon DH, Dore MP, Kim JJ, et al. High-level β-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003;47:2169-78.
74. Godoy APO, Ribeiro ML, Benvengo YHB, et al. Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol 2003;3:20.
75. Wu H, Shi XD, Wang HT, et al. Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxicillin. J Antimicrob Chemother 2000;46:121-3.
76. Trieber CA, Taylor DE. Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol 2002;184:2131-40.
77. Gerrits MM, de Zoete MR, Arents NL, et al. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother 2002;46:2996-3000.
78. Dailídiene D, Bertoli MT, Miciuleviciene J, et al. Emergence of tetracycline resistance in Helicoboder pylori: multiple mutational changes in 16S ribasomal DMA and other genetic loci. Antimicrob Agents Chemother 2002;46:3940-6.
79. Gerrits MM, Berning M, Van Vliet AH, et al. Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003;47:2984-6.
80. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Results of a Multicentre European Survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992;9:777-81.
81. Glupczynski Y, Broutet N, Cantagrel A, et al. Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002;21:549-52.
82. Mendz GL, Mégraud F. Is the molecular basis of metronidazole resistance in microoerophilic organisms understood? Trends Microbiol 2002;10:370.
83. Chisholm SA, Owen RJ. Mutations in Helicobacter pylori rdxA gene sequences may not contribute to metronidazole resistance. J Antimicrob Chemother 2003;51:995-9.
84. Marais A, Bilardi C, Cantet F, et al. Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res Microbiol 2003;154:137-44.
85. Moore RA, Beckthold B, Wong S, et al. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995;39:107-11.
86. Tankovic J, Lascols C, Sculo Q, et al. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003;47:3942-4.
87. Heep M, Beck D, Bayerdorffer E, et al. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999;43:1497-9.
88. Fujimura S, Kato S, Kawamura T, et al. In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults. J Antimicrob Chemother 2002;49:541-3.
89. Heep M, Rieger U, Beck D, et al. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000;44:1075-7.
90. Heep M, Beck D, Bayerdorffer E, et al. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999;43:1497-9.
91. Heep M, Rieger U, Beck D, et al. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000;44:1075-7.
92. Mégraud F, Doermann HP. Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 1998;43:S61-5.
93. Houben MHMG, van de Beek D, Hensen EF, et al. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047-55.
94. Bochenek WJ, Peters S, Fraga PD, et al. Helicobacter pylori Pantoprazole Eradication (HELPPE) Study Group. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies, Helicobacter 2003;8:626-42.
95. Ducons JA, Santolaria S, Guirao R, et al. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999;13:775-80.
96. Hoshiya S, Watanabe K, Tokunaga K, et al. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J Gastroenterol 2000;35:10-14.
97. Kalach N, Benhamou PH, Campeotto F, et al. Clarithromycin resistance and eradication of Helicobacter pylori in children. Antimicrob Agents Chemother 2001;45:2134-5.
98. Katelaris PH, Forbes GM, Talley NJ, et al. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE study. Gastroenterology 2002;123:1763-9.
99. Kawabata H, Habu Y, Tomioka H, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003;17:259-64.
100. Kihira K, Satoh K, Saifuku K, et al. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1083-7.
101. Lamouliatte H, the Aquitaine Gastro Association, Samoyeau R, et al. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1999;13:1523-30.
102. Lamouliatte H, Mégraud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003;18:791-7.
103. Lehmann FS, Drewe J, Terracciano L, et al. Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 2000;14:305-9.
104. Lind T, Mégraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248-53.
105. McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003;139:463-9.
106. Miki I, Aoyama N, Sakai T, et al. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 2003;15:27-33.
107. Murakami K, Sato R, Okimoto T, et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002;16:1933-8.
108. Peitz U, Sulliga M, Wolle K, et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002;16:315-24.
109. Pilotto A, Leandro G, Franceschi M, et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther 1999;13:667-73.
110. Poon SK, Chang CS, Su J, et al. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment Pharmacol Ther 2002;16:291-6.
111. Tankovic J, Lamarque D, Lascols C, et al. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy or the omeprazole-amoxicillin- clarithromycin therapy. Aliment Pharmacol Ther 2001;15:707-13.
112. Bozzoli F, Zagari M, Pozzato P, et al. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther 1998;12:439-45.
113. Ellenrieder V, Boeck W, Richter C, et al. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand J Gastroenterol 1999;34:750-6.
114. Hurenkamp GJ, van der Ende A, Grundmeijer HG, et al. Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. Aliment Pharmacol Ther 2000;14:1065-70.
115. Savarina V, Zentilin P, Pivari M, et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000;14:893-900.
116. Bardhan KD, Morton D, Perry MJ, et al. Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 2001;15:1199-204.
117. Sung JJY, Chn FKL, Wu JCY, et al. One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. Aliment Pharmacol Ther 1999;13:1079-84.
118. Mégraud F, Roberts P, Williamson R. Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. Helicobacter 2000;5:222-6.
119. O'Morain C, Borody T, Parley A, et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 2003;17:415-20.
120. Bardhan K, Bayerdorffer E, Veldhuyzen Van Zanten SJ, et al. The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 2000;5:196-201.
121. Bayerdorffer E, Lonovics J, Dite P, et al. Efficacy of two different dosage regimens of omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13:1639-45.
122. Isomoto H, Inoue K, Furusu H, et al. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2003;18:101-7.
123. Murakami K, Sato R, Okimoto T, et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002;16:1933-8.
124. Miwa H, Nagahara A, Kurosawa A, et al. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 2003;17:1545-51.
125. Neri M, Milano A, Laterza F, et al. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment Pharmacol Ther 2003;18:821-7.
126. Romano M, Iovene MR, Montella F, et al. Pretreatment antimicrobial- susceptibility testing in the eradication of H. pylori infection. Am J Gastroenterol 2000;95:3317-18.
127. Toracchio S, Cellini L, Di Campli E, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:1639-43.
128. Hua JS, Zheng PY, Fong TK, et al. Helicobacter pylori acquisition of metronidazole resistance by natural transformation in vitro. World J Gastroenterol 1998;4:385-7.
129. Grignon B, Tankovic J, Mégraud F, et al. Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori. Microb Drug Res 2002;8:61-6.
130. Owen RJ. Molecular testing for antibiotic resistance in Helicobacter pylori. Gut 2002;50:285-9.
131. Versalovic J, Shortridge D, Kliber K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996;40:477-80.
132. Occhialini A, Urdaci M, Doucet-Populaire F, et al. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribasomes. Antimicrob Agents Chemother 1997;41:2724-8.
133. Stone GG, Shortridge D, Versalovic J, et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother 1997;41:712-14.
134. Pina M, Occhialini A, Monteiro L, et al. Detection of point mutations associated with resistance of Helicobacter pylori to clarithromycin by hybridization in liquid phase. J Clin Microbiol 1998;36:3285-90.
135. Marais A, Monteiro L, Occhialini A, et al. Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. Gut 1999;44:463-7.
136. Maeda S, Yoshida H, Matsunaga H, et al. Detection of clarithromycin- resistant H. pylori strains by a preferential homoduplex formation assay. J Clin Microbiol 2000;38:210-14.
137. van Doorn LJ, Debets-Ossenkopp YJ, Marais A, et al. Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance. Antimicrob Agents Chemother 1999;43:1779-82.
138. Alorcón T, Domingo D, Prieto N, et al. PCR using 3′-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates. J Clin Microbiol 2000;38:923-5.
139. Scarpellini P, Carrera P, Cavallero A, et al. Direct detection of Helicobacter pylori mutations associated with macrolide resistance in gastric biopsy material taken from human immunodeficiency virus-infected subjects. J Clin Microbiol 2002;40:2234-7.
140. Gibson JR, Saunders NA, Burke B, et al. Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. J Clin Microbiol 1999;37:3746-8.
141. Chisholm SA, Owen RJ, Teare EL, et al. PCR-based diagnosis of Helicobacter pylori: infection and real-time deterination of clarithromycin resistance directly from human gastric biopsy samples. J Clin Microbiol 2001;39:1217-20.
142. Matsumura M, Hikiba Y, Ogura K, et al. Rapid detection of mutations in the 23S rRNA gene of Helicobacter pylori that confers resistance to clarithromycin treatment to the bacterium. J Clin Microbiol 2001;39:691-5.
143. Olsastro M, Ménard A, Santos A, et al. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol 2003;4:397-402.
144. Lascols C, Lamarque D, Costa JM, et al. Fast and accurate quantitative detection of Helicobacter pylori and identification of clarithromycin resistance mutations in H. pylori isolates from gastric biopsy specimens by real-time PCR. J Clin Microbiol 2003;41:4573-7.
145. Trebesius K, Panthel K, Strobel S, et al. Rapid and specific detection of Helicobacter pylori macralide resistance in gastric tissue by fluorescent in situ hybridisation. Gut 2000;46:608-14.
146. Wittwer CT, Ririe KM, Andrew RV, et al. The Lightcycler™: a microvolume multisample fluorimeter with rapid temperature control. BioTechniques 1997;22:176-81.
147. Schabereiter-Gurtner C, Dragosics B, Puz S, et al. Detection of Helicobacter pylori infection and determination of clarithromycin resistance in stool specimens by real-time PCR. Helicobacter 2003;8:480.
148. Ménard A, Santos A, Mégraud F, et al. PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. Antimicrob Agents Chemother 2002;46:1156-7.
149. Russmann H, Kempf VA, Koletzko S, et al. Comparison of fluorescent in situ hybridization and conventional culturing for detection of Helicobacter pylori in gastric biopsy specimens. J Clin Microbiol 2001;39:304-8.
150. Feydt-Schmidt A, Russmann H, Lehn N, et al. Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. Aliment Pharmacol Ther 2002;16:2073-9.
151. Russmann H, Feydt-Schmidt A, Adler K, et al. Detection of Helicobacter pylori in paraffin-embedded and in shock-frozen gastric biopsy samples by fluorescent in situ hybridization. J Clin Microbiol 2003;41:813-15.
152. Latham SB, Owen RJ, Elviss NC, et al. Differentiation of metronidazole-sensitive and -resistant clinical isolates of Helicobacter pylori by immunoblotting with antisera to the RdxA protein. J Clin Microbiol 2001;39:3052-5.
153. Latham SR, Labigne A, Jenks PJ. Production of the RdxA protein in metronidazole-susceptible and -resistant isolates of Helicobacter pylori cultured from treated mice. J Antimicrob Chemother 2002;49:675-8.
154. Pelerito A, Oleastro M, Labigne A, et al. Analysis of Helicobacter pylori's penicillin-binding proteins (PBPs) natural polymorphism, therapeutical targets of the family of β-lactam antibiotics. Helicobacter 2003;8:394.